Akihiko Gemma

8PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|May 19, 2026
Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.

|May 14, 2026
Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.

|Apr 21, 2026
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

|Feb 02, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada

|Dec 11, 2025
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).

Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi

Pageof 2

Frequent Collaborators

5 joint publications

Makoto Nishio

4 joint publications

Yasushi Goto

3 joint publications

Hiroshige Yoshioka

3 joint publications

Tetsuya Mitsudomi